Healthcare
Swiss Pharma Giant Plans German Expansion
Novartis is building a EUR 35 million new production facility in the eastern German city of Halle.
Nov 11, 2025
The new location will be specialized in cancer therapies, specifically drugs using radioligands - cancer-seeking molecules attached to radioactive isotopes. They represent one of Novartis’ three strategic therapy platforms.
If all goes to plan, the facility will open in late 2027. Future expansions are possible.
“Germany has established structures and excellent expertise in the area of radioligand therapy,” Novartis Germany CEO Manfred Heinzer said in a statement. “Wherever innovation is valued and targeted for promotion, there will be investment, value creation and progress.”
Halle mayor Alexander Vogt hailed Novartis’ decision a “coup” for his city, which has a large airport and is near to nuclear medicine centers in central Germany and Berlin.
